Continuing Education (CME)
Adult Molecular Tumor Board
Enduring Webinar: Molecular Stratification and Novel Therapeutic Approaches for Meningioma
Enduring CME Activity
Activity Launch Date: June 9, 2026
Activity Expiration Date: June 9, 2028
The deadline to claim CE Credit and claim Certificate of Participation is Friday June 9, 2028, at 11:59 pm ET.
This activity is provided by the Society for Neuro-Oncology.
Please note, if you participated in the live activity, you are not eligible to claim credit for the enduring activity.
Target Audience
Neuro-oncologists, medical oncologists, neurosurgeons, neurologists, radiation oncologists, radiologists, neuropathologists, physicians/scientists, clinical and laboratory trainees, and allied health professionals
Statement of Need/Program Overview
Advances in the molecular characterization of meningioma have transformed our understanding of this historically heterogeneous tumor group. Copy number alterations, gene mutations, and epigenetic signatures now offer a more precise framework for stratifying risk and predicting clinical behavior beyond traditional histopathology.
In parallel, emerging imaging modalities—including advanced PET/MRI techniques and theranostic approaches—are providing new opportunities to non‑invasively assess tumor biology, guide treatment decisions, and monitor response.
This session will synthesize current knowledge on the molecular landscape of meningioma, highlighting how specific genomic and chromosomal alterations inform prognosis and therapeutic selection. Novel imaging strategies and their clinical applications will be reviewed, emphasizing their role in refining diagnosis and surveillance. Finally, the session will examine contemporary management approaches, including surgery, radiation, and systemic therapies, and will explore targeted and biologically informed treatments now in development. Together, these perspectives underscore the growing potential for precision medicine to reshape the care of patients with meningioma.
Educational Objectives
After participating in this CME activity, participants should be able to:
-
Describe copy number and other molecular alterations that enable more precise stratification of meningioma.
-
Evaluate novel imaging approaches for meningioma and their clinical application.
-
Review current therapeutic approaches for meningioma and targeted approaches in development.
Program Agenda
Agenda
Physician Accreditation Statement
The Society for Neuro-Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation
The Society for Neuro-Oncology designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Instructions to Receive Credit, Claim Certificate of Participation
- Register for the enduring activity through the Neuro-Oncology Academy.
- View the entire recording.
- Complete the evaluation and application for credit.
- Download the CME certificate or certificate of participation from "My Learning Dashboard" located on the left-hand side menu bar.
- Cerficiates of credit should be claimed by physicians (MD, DO, MD/PhD).
- Certificates of participation should be claimed by non-physicians.
Activity Expiration Date: June 9, 2028. Deadline to claim CE Credit will be June 9, 2028, at 11:59 pm ET.
Disclosure of Relevant Financial RelationshipsThe Society for Neuro-Oncology (SNO) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited Continuing Education, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of accredited continuing education program are required to disclose all financial relationships with any ineligible company within the past 24 months . All financial relationships reported are identified as relevant and mitigated by Society for Neuro-Oncology lin accordance with the Standards for Integrity and Independence in Accredited Continuing Education in advance of delivery of the activity to learners. The content of this activity has been vetted to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by SNO. To view the list of disclosures,
click here.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Society for Neuro-Oncology does not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
SNO CME Contact Information
For information about the accreditation of this program, please contact the Society for Neuro-Oncology CME Program Manager, MeLesa Buchanan, RN at
melesa@soc-neuro-onc.org
For techical assistance with claiming CME credit or certificate of participation, please email
academy@soc-neuro-onc.org.
